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Abstract 
Background: Post traumatic stress disorder (PTSD) and depressive disorder are over 
represented in combat veterans.  Veterans with both disorders have an increased risk of 
suicide.  The nitric oxide synthase 1 adaptor protein (NOS1AP) gene, which modulates stress-
evoked N-methyl-D-aspartate (NMDA) activity, was investigated in combat veterans.  
Methods: A comprehensive genetic analysis of NOS1AP and its association with PTSD was 
investigated in Vietnam combat veterans with PTSD (n=121) and a group of healthy control 
individuals (n=237).  PTSD patients were assessed for symptom severity and level of 
depression using the Mississippi Scale for Combat-Related PTSD and the Beck Depression 
Inventory-II (BDI). 
Results:  The G allele of NOS1AP SNP rs386231 was significantly associated with PTSD (p 
= 0.002).  Analysis of variance revealed significant differences in BDI-II and Mississippi 
scores between genotypes for rs386231 with the GG genotype associated with increased 
severity of depression (p = 0.002 F = 6.839) and higher Mississippi Scale for Combat-
Related PTSD scores (p = 0.033).  Haplotype analysis revealed that the C/G haplotype 
(rs451275/rs386231) was significantly associated with PTSD (p = 0.001).   
Limitations: The sample sizes in our study were not sufficient to detect SNP associations with 
very small effects.  In addition the study was limited by its cross sectional design.  
Conclusions: This is the first study reporting that a variant of the NOS1AP gene is associated 
with PTSD.  Our data also suggest that a genetic variant in NOS1AP may increase the 
susceptibility to severe depression in patients with PTSD and increased risk for suicide. 
Keywords:  polymorphism, genetics, PTSD, depression, nitric oxide synthase 1 adaptor 
protein, suicide 
Introduction 
Posttraumatic stress disorder (PTSD) is an anxiety disorder that manifests after exposure to 
psychological trauma.  A variety of traumatic events can lead to PTSD with stress associated 
with military combat being a common experience.  Combat related PTSD is associated with 
chronicity, increased disability and is more frequently associated with other conditions 
(Prigerson et al., 2001).  Not all individuals exposed to combat trauma develop PTSD and 
substantial evidence derived from family and adoption studies suggest a genetic influence on 
individual susceptibility for this disorder (Davidson et al., 1989; Reich et al., 1996).  Twin 
studies of Vietnam veterans have confirmed genetic factors contribute approximately 30% of 
the variance for PTSD susceptibility (Koenen et al., 2002; Lyons et al., 1993; True et al., 
1993).   
Depressive disorder and PTSD are frequently comorbid.  Genes have been identified that are 
common to both disorders (Koenen et al., 2008; Lawford et al., 2006).  Co-occurrence of 
these two disorders is associated with diminished quality of life, reduced life satisfaction and 
increased severity of PTSD symptomatology (Ikin et al., 2010).  Suicidal behaviour is more 
common in individuals suffering both disorders compared to those with depressive disorder 
alone (Oquendo et al., 2003).  Coexistent depressive disorder and PTSD have an additive 
effect on risk for suicidal ideation in war veterans (Sher, 2009).  Suicide is a major problem 
among war veterans and represents a fatal outcome of PTSD.  In 2009 during the DOD/VA 
Mental Health Summit in Washington, D.C., U.S Veterans Affairs Secretary Eric K Shineski 
stated that more veterans committed suicide between 2001-2009 than were killed in Iraq and 
Afghanistan (http://www.defense.gov/news/newsarticle.aspx?id=56404).  
A number of genes have been identified to be associated with increased risk for PTSD alone 
[reviewed in (Yehuda et al., 2011)].  Dopamine regulating genes including the dopamine 
receptor D2 (DRD2) are associated with PTSD (Comings et al., 1996; Voisey et al., 2009).  A 
polymorphism in the promoter of the serotonin transporter gene has also been implicated in 
PTSD risk (Grabe et al., 2009; Kolassa et al., 2010; Lee et al., 2005).  More recently, a non-
synonymous polymorphism in brain–derived neurotrophic factor (BDNF) was found to be 
associated with psychotic symptoms in PTSD (Pivac et al., 2012).  A variation in the 
serotonin transporter gene may also be involved in a gene-environment interaction (Caspi et 
al., 2010).  The variation is associated with an increased risk of depression following 
exposure to childhood maltreatment (Karg et al., 2011).  Adding to the importance of 
environmental risk, a study of maltreated children showed positive social support protected 
against depression even in children who carried the serotonin transporter gene risk variant 
(Kaufman et al., 2006).   
PTSD may be associated with diminished basal cortisol levels and increased sensitivity to 
stress and negative feedback (Yehuda, 2006).  Furthermore hippocampal atrophy associated 
with PTSD may be due to the altered stress hormone physiology associated with this disorder 
(Bremner et al., 1995).  Identifying genes that modulate the actions of glucocorticoids may 
identify novel SNPs associated with PTSD.  The NOS1AP gene encodes nitric oxide synthase 
1 adaptor protein that binds to the signalling molecule, neuronal nitric oxide synthase 
(nNOS).  Nitric oxide (NO) is produced from its precursor L-arginine by the enzyme NO 
synthase (NOS) which includes at least three distinct isoforms - neuronal, endothelial, and 
inducible NOS.  NO release is involved in the activation of glutamate N-methyl-D-aspartate 
(NMDA) receptors (Southam and Garthwaite, 1993).  NOS1AP competes with PSD-95 
(postsynaptic density protein-95) for nNOS binding and is thought to reduce NMDA receptor 
signalling via PSD-95 and nNOS.  An earlier study that first identified NOS1AP found that 
overexpression of NOS1AP results in a loss of PSD-95/nNOS complexes in transfected cells 
(Jaffrey et al., 1998).  The NO cascade is also involved in hippocampal volume loss and 
cognitive deficits found in PTSD (Elzinga and Bremner, 2002).  During stress, glutamate, 
which increases risk of hippocampal atrophy, is released via increased sensitivity of 
hippocampal glucocorticoid receptors (Sapolsky, 2001).  Animal studies have found stress 
mediated glucocorticoid release activated NOS activity leads to down-regulation of 
hippocampal NMDA receptors and total GABA levels (Harvey et al., 2004).  A partial 
agonist, D-cycloserine of the NMDA receptor has shown promise in the treatment of PTSD 
(Heresco-Levy et al., 2002). 
On the basis that the NO pathway has been shown to be associated with general 
psychological distress (Harvey et al., 2004; Luciano et al., 2012), anxiety (Weitzdoerfer et al., 
2004) depression (da Silva et al., 2000; Harkin et al., 1999; Yildiz et al., 2000) and 
hippocampal atrophy we employed a candidate gene approach to investigate whether or not 
PTSD was associated with NOS1AP.  Furthermore as the NO pathway is involved with 
depression a possible association between NOS1AP and depressive symptoms was explored.  
We hypothesize that genetic variation in NOS1AP may increase an individual’s risk for PTSD 
by affecting glucocorticoid mediated glutamate release. 
  
Methods 
Subjects 
PTSD  
A total of 121 unrelated male Caucasian patients meeting Diagnostic and Statistical Manual 
of Mental Disorders-IV (DSM-IV) criteria for PTSD were recruited at the Greenslopes 
Private Hospital for the study.  Patients were recruited when they presented at hospital for 
initial assessment and treatment.  None had received treatment for a psychiatric disorder or 
had been treated with psychotropic medication.  Following PTSD assessment with a 
psychiatrist, treatment was then commenced.  Exclusion criteria for the study included a 
diagnosis of psychosis, bipolar disorder, obsessive compulsive disorder, or organic brain 
syndrome including dementia and opiate dependence.  Participants had a mean age of 52 
years of age (s.d.  6.2).  All subjects were Vietnam combat veterans who had served in the 
Australian Armed Forces.  All subjects had sufficient comprehension of English and could 
understand the administered questionnaires.  Patients were assessed for PTSD by a consultant 
psychiatrist or a senior psychiatric registrar using DSM-IV criteria.  Furthermore, PTSD 
caseness was confirmed by every patient exceeding the clinical cut-off score of 94 on the 
Mississippi Scale for Combat-Related PTSD (Keane et al., 1988).  The validity and reliability 
of this scale in veterans are well established (Keane et al., 1988).  Patients were also 
administered the Beck Depression Inventory: second edition (BDI-II). The BDI-II is designed 
to assess the severity of depression in adolescents and adults by addressing DSM-IV criteria 
for depression.  The BDI-II is positively correlated with other psychological tests including 
the Scale for Suicide ideation and the Hamilton Psychiatric Rating Scale for Depression 
(Beck et al., 1996).  For each question, severity of symptoms are rated using a four-point 
scale from mild (0) to severe (3).  Total scores lower than nine are classified as within the 
normal range, 10-15 as mild depression, 16-23 as moderate depression and 24-63 as severe 
depression.  Patient clinical history and demographic data including ethnic background were 
also obtained.  After the procedure had been fully explained, all participants provided written 
informed consent.  They were able to terminate their involvement at any time during the 
interview without prejudice.  Institutional ethics approval was obtained from the Greenslopes 
Private Hospital. 
Controls 
The control group consisted of 237 unrelated Caucasians (98 female and 139 male) with a 
mean age of 36.8 years (s.d. ± 12.8 years).  The control group consisted of volunteers from 
the general public, hospital nursing and medical staff, and university staff and students.  
Formal screening for psychological disorders was not undertaken in the control population.  
As such the controls represent an unselected control group.  Controls were recruited in the 
Brisbane region (a city of approximately 2 million inhabitants on the East Coast of Australia) 
and all were of Caucasian descent.   
Selection of SNPs 
Using the International HapMap project phase II (International HapMap, 2003), thirteen tag-
SNPs in NOS1AP with a minor allele frequency cut-off of 0.15 were selected.  Tag-SNPs 
were identified using the pair-wise option of Tagger with a threshold of r2 > 0.8.   
Genotyping 
Oragene kits were used to extract DNA from saliva samples.  Samples were genotyped using 
a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility.  The hME assay is based on the annealing of an oligonucleotide primer 
(hME primer) adjacent to the SNP of interest.  The addition of a DNA polymerase along with 
a mixture of terminator nucleotides allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products, each having a unique 
molecular mass.  The resultant masses of the extension products are then analysed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
a genotype is assigned in real time.   
Statistical Analysis 
A Fisher’s exact test was performed to identify statistical associations between genotype and 
disease status.  A Pearson’s chi-squared test was performed to identify statistical associations 
between allele and disease status.  Odds ratios (OR) were also calculated.  Tests were 
performed on both genotype and allele data.  Statistical tests were performed using the 
COMPARE2 program from the WinPepi suite of epidemiology programs (Abramson, 2004) 
and SPSS version 16.  Hardy-Weinberg equilibrium (HWE) was computed using Utility 
Programs for Analysis of Genetic Linkage (Ott, 1988).  Correction for multiple testing was 
conducted using the false detection rate (FDR) method (Benjamini and Hochberg, 1995).  
Haplotypes were generated and analysed for linkage disequilibrium (LD) measures (D' and 
r2) using JLIN (Carter et al., 2006).   
  
Results 
Genotype analysis 
Using a haplotype block based gene-tagging approach, a comprehensive analysis of NOS1AP 
SNPs and their association with PTSD was investigated.  A total of 13 tag-SNPs were 
genotyped in 121 PTSD cases and 237 controls.  One SNP, rs386231, was found to be 
significantly associated with PTSD at the allele level (Table 1).  The rs386231 SNP was 
investigated further at the genotype level and remained significant (Table 2).  The GG 
genotype was three times as likely to be associated with PTSD compared to the AA genotype.  
The attributable fraction of rs386231 was calculated using genotypes counting the presence 
of the G-allele as a risk factor.  The attributable fraction, which is the proportion of cases in 
the study population that would not have occurred had the risk factor (risk allele) not have 
been present, is a useful measure to quantify the impact of the allele on the development of 
PTSD (Lappalainen et al., 2002).  This analysis revealed that 10.42% (95% CI = 3.09 -
17.75%) of the susceptibility to PTSD could be attributed to having the GG genotype of the 
rs386231 SNP.  This SNP survived correction for multiple testing (corrected α-value 0.004) 
at the allele level but not genotype level.  Genotype frequencies indicated that this SNP was 
in HWE in both cases and controls.   
Since the PTSD group included males only we also analysed our data using male only 
controls.  The association of rs386231 with PTSD still remained significant (p = 0.018) but 
was lower in significance due do decrease in power of the smaller sample size.   
Haplotype analysis 
In order to select SNPs to include in the haplotype analysis we looked for SNPs that showed 
independent association with PTSD.  We therefore performed the haplotype analysis using 
rs386231 and rs4531275, as rs 4531275 was the only other SNP approaching significance and 
it showed low disequilibrium with rs386231.  Haplotype frequencies for the two SNPs are 
shown in Table 3.  The C/G haplotype (rs451275/rs386231) was significantly associated with 
PTSD and was 1.8 times as likely to be associated with PTSD compared to the most common 
haplotype (C/A).   
 
Linkage disequilibrium 
Linkage disequilibrium analysis was performed on all 13 SNPs for both PTSD and control 
populations (Figure 1) revealing strong LD with SNPs in close proximity only.  The rs386231 
and rs4531275 SNPs were in weak linkage disequilibrium (LD) in both the control 
population D' = 0.109 and r2 = 0.010 and PTSD population D' = 0.054 and r2 = 0.002.   
Analysis of severity and depressive symptoms 
PTSD patients were analysed for symptom severity and level of depression using the 
Mississippi Scale and the Beck Depression Inventory (BDI).  Only one individual was in the 
normal range for depression (BDI-11 <9), 6 had mild depression (BDI-11 10-15) and all 
other PTSD patients had moderate to severe depression according to their BDI-11 score.  
Analysis of variance revealed significant differences in BDI-II scores between genotypes (p = 
0.002 F = 6.839).  PTSD patients carrying the GG genotype had a mean BDI-II score of 35 
(95% CI = 30.66-39.34) which is a measure of severe depression.  Post-hoc pairwise 
comparisons including Tukey and Bonferroni tests were undertaken to test differences 
between groups.  Patients with PTSD carrying the GG genotype had higher BDI scores 
compared to patients carrying the AG genotype (Tukey p = 0.001, Bonferroni p = 0.001) or 
the AA genotype (Tukey p = 0.021, Bonferroni p = 0.023) (Figure 2).  There was no 
difference between the GA and AA genotypes (Tukey p = 0.4 and Bonferroni p = 0.6).   
Analysis of variance also revealed significant differences in Mississippi scores between 
genotypes (p = 0.031 F = 3.631).  PTSD patients carrying the GG genotype had a mean 
Mississippi score of 140 (95% CI = 129 - 152) which is a measure of symptom severity.  
Patients with PTSD carrying the GG genotype had higher Mississippi scores compared to 
patients carrying the AA genotype (Tukey p = 0.033, Bonferroni p = 0.037) or the AG 
genotype (Tukey p = 0.046, Bonferroni p = 0.053) (Figure 3).   
  
Table 1  Association of allele frequencies of 13 NOS1AP SNPs with PTSD 
SNP Position Allele frequency 2 P Odds Ratioa 
rs945706 160343177 A  C  0.052 0.819 1.04 (0.73-1.48) 
Control  316 136    
PTSD  163 73 
rs1415259 160351933 A  G  0.194 0.659 1.08 (0.65-1.31) 
Control  293 153    
PTSD  159 77 
rs4656355 160390421 A  G  0.158 0.691 1.07 (0.66-1.32) 
Control  154 286    
PTSD  79 157 
rs6704393 160418680 C  T  0.299 0.585 1.10 (0.78-1.54) 
Control  306 156    
PTSD  154 86 
rs1415263 160432667 C  T  0.000 0.998 1.00 (0.70-1.41) 
Control  298 150    
PTSD  157 79 
rs4531275 160453174 C T  1.759 0.185 1.28 (0.53-1.14) 
Control  324 126    
PTSD  178 54 
rs6683968 160458036 G  T  0.652 0.419 1.16 (0.59-1.25) 
Control  312 126     
PTSD  175 61 
rs4657178 160477234 C  T  0.125 0.724 1.07 (0.62-1.39) 
Control  349 97    
PTSD  189 49 
rs2341744 160535646 A  G  0.976 0.323 1.20 (0.57-1.21) 
Control  225 217    
PTSD  130 106 
rs347300 160566447 A  G  0.409 0.523 1.11 (0.79-1.55) 
Control  288 164    
PTSD  147 93 
rs1858232 160570462 A  G  1.078 0.299 1.18 (0.61-1.18) 
Control  311 127    
PTSD  176 60 
rs347313 160570900 A  G  0.688 0.407 1.15 (0.63-1.22) 
Control  192 248    
PTSD  96 142 
rs386231 160592447 A  G  9.196  0.002 1.69 (1.18-2.40) 
Control  346 114    
PTSD  153 85 
a Odds Ratio with 95% Fisher’s exact confidence interval. 
 
 
Table 2 Association of genotype frequencies of rs386231 in patients with PTSD compared 
with controls  
rs386231 Genotype counts (%) p-value* 
 AA AG GG  
Control 130 (56.5) 86 (37.4) 14 (6.1) 0.008 
†0.002 PTSD 52 (43.7) 49 (41.2) 18 (15.1) 
Odds Ratio‡ 
   (p-value) 
1.000 
 
1.424 
(0.291) 
3.214 
(0.006) 
 
* p-value determined by Pearson’s χ2 test 
† p-value determined using the extended Mantel-Haenszel test for trend in a given direction 
 
  
Table 3  Haplotype analysis of rs4531275 and rs386231 polymorphisms in patients with 
PTSD compared to controls 
Haplotype* Controls  PTSD  Odds Ratio** (P) χ2**** P 
CA 249 117 1 1.358 0.244 
CG 72 61 1.803 (0.014) 10.526 0.001 
TA 86 32 0.792 (0.951) 2.951 0.086 
TG 41 20 1.038 (1.000) 0.039 0.844 
TOTAL 448 230  11.288 0.010 
 
* Haplotype frequencies were estimated using JLIN.  Note, haplotypes with a missing 
genotype were omitted from the analysis. Allele order is rs4531275/rs386231 
** Odds ratio with respect to the CA haplotype which is more commonly associated with a 
normal phenotype 
*** Likelihood ratio 2 test comparing haplotype frequency between groups when all other 
haplotypes were pooled 
  
Discussion 
Although the NO pathway is associated with psychological distress (Harvey et al., 2004; 
Luciano et al., 2012), anxiety (Weitzdoerfer et al., 2004) and depression (da Silva et al., 
2000; Harkin et al., 1999; Yildiz et al., 2000), a role of NOS1AP in PTSD susceptibility has 
not previously been investigated.  This study represents the first evidence of an association 
with NOS1AP variation and PTSD.  As NOS1AP is a key player in NMDA glutamate 
neurotransmission, many studies have investigated its role in schizophrenia with both positive 
(Brzustowicz et al., 2004; Kremeyer et al., 2009; Wratten et al., 2009; Xu et al., 2005) and 
negative associations found (Husted et al., 2010; Puri et al., 2006).  Also NOS1AP mRNA 
expression is significantly decreased in brain tissue from bipolar patients treated with 
antipsychotics compared to untreated patients (Xu et al., 2005).  Although NOS1AP has been 
studied in schizophrenia susceptibility, this is the first study to investigate a role in PTSD and 
depressive disorder.  As NOS1AP has been shown to be associated with the cognitive defects 
found in schizophrenia a role in cognitive deficits associated with PTSD is likely.  NOS1AP 
variants could influence stress induced NOS activity and subsequently effect NMDA 
receptors and GABA pathways.  This may lead to the stress-related hippocampal 
degeneration and cognitive defects seen in PTSD patients. 
NOS1AP is involved in signal transduction in the NMDA receptor system and NMDA 
pathways play a role in the predisposition of PTSD (Tamaki et al., 2008; Yamamoto et al., 
2008) .  Analysis of 13 tag-SNPs in NOS1AP revealed associations with PTSD at the 
genotype and allele level for an intronic SNP, rs386231, in Vietnam combat veterans.  
Individuals carrying the GG genotype were more than three times likely to have PTSD 
compared to those with the AA genotype.  More importantly, we found the GG genotype to 
be associated with more PTSD symptoms and increased severity of depression.  This is 
consistent with studies that have found a genetic correlation with depressive symptoms in 
PTSD patients (Goenjian et al., 2012; Goenjian et al., 2008; Koenen et al., 2008). 
The function of NOS1AP was investigated after earlier knock-out mice studies of its binding 
partner nNOS revealed reduced NMDA receptor-dependent dendritic growth in motor 
neurons (Inglis et al., 1998).  Knockdown studies of the long isoform of NOS1AP reveal an 
increase in dendrite number (Carrel et al., 2009) which may explain dendritic abnormalities 
in schizophrenia and other mood disorders.  NOS1AP regulates both dendritic patterning 
(Carrel et al., 2009) and dendritic spine development (Richier et al., 2010).  Reduced cortical 
dendritic branching is found in depressed subjects who commit suicide compared to sudden-
death controls suggesting reduced dendritic branching predisposes to depression with a fatal 
outcome (Hercher et al., 2010).  Dendritic remodelling in response to stress induced N-methyl 
D-aspartate (NMDA) release has been proposed as a fundamental aetiological factor in the 
development of anxiety and depressive disorders following chronic stress and stressful life 
events (Gorman and Docherty, 2010).  Stress is a major factor in the development of anxiety 
and depressive disorders (Kendler et al., 2004) and chronic stress reduces dendritic 
branching, length and spine number in the hippocampus (Liston et al., 2006) and the 
prefrontal cortex (Radley et al., 2004) of rats. 
Fluoxetine, an agent used to treat anxiety and depressive disorders, increases hippocampal 
dendritic spine and synapse formation in the rat (Hajszan et al., 2005).  Furthermore, 
reboxetine decreases glutamate receptor expression both in the hippocampus and prefrontal 
cortex (Barbon et al., 2006).   
NO release following stress-evoked NMDA receptor activation in animals is an important 
vulnerability factor in the depressive phenotype (Wegener et al., 2010).  Animals that are 
genetically vulnerable to stress, display significant changes within the NMDA–NOS 
signalling cascade in the hippocampus compared to controls even when subjected to mild 
stress.  NOS1AP may decrease NMDA complex signal transduction resulting in reduced 
functioning of that system (Brzustowicz et al., 2004).  NOS1AP also competes with PSD-95 
for binding to nNOS and this study suggests that NOS1AP prevents excessive NO release 
following raised NMDA activity (Wegener et al., 2010).  Our study has shown that a genetic 
variation in NOS1AP is associated with increased severity of depression in a cohort of PTSD 
patients.  Genetic variation in NOS1AP may interfere with the protective role NOS1AP plays 
in NMDA–NOS response and mediate the effect of stress on dendrites.   
We also observed a haplotype with the rs386231G allele and the rs4531275 C allele to be 
associated with PTSD.  The rs4531275 SNP on its own was not associated with PTSD but as 
a haplotype with rs386231 was slightly more significant than the rs386231 association.  It is 
in weak LD with rs386231 and therefore may have a role in PTSD susceptibility but only as a 
haplotype with rs386231.   
Limitations of the study include the following.  This study recruited male war veterans only 
and the results may not be generalized to females or individuals who were exposed to trauma 
other than combat.  Population stratification cannot be ruled out and therefore our results 
need to be confirmed independently.  The sample size may have been insufficient to detect 
SNPs with very small effects.  However we did have sufficient power to detect a strong 
NOS1AP SNP association with PTSD.  In our study we used a control population drawn from 
a normal population who had possibly been exposed to a traumatic event.  Further studies 
should also use a control population that has been exposed to combat but that does not have 
PTSD.  Furthermore the study was cross sectional in design and veterans were assessed for 
depression many years following their traumatic experiences.  Future studies should employ a 
prospective design.   
Our results support the hypothesis that NOS1AP contributes to depression following a 
stressful event.  The study strengthens the observation that the NO pathway through NMDA 
signalling is important in determining individual response to stress.  The identification of 
genes that predispose to PTSD risk can be used in the future help identify those particularly at 
risk for this disorder. Furthermore identification of individuals prone to both depression and 
PTSD could allow for early intervention and treatment and hopefully reduce the unacceptable 
suicide rate found in combat veterans.  
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